Advertisement
Canadian Journal of Cardiology

Usefulness of Left Ventricular Assist Device in the Recovery of Severe Amphetamine-Associated Dilated Cardiomyopathy

Published:October 12, 2019DOI:https://doi.org/10.1016/j.cjca.2019.09.024

      Abstract

      Exposure to synthetic drugs such as amphetamines may lead to significant consequences on the cardiovascular system. The prognosis of young adults with amphetamine-induced cardiomyopathy remains poor. We present 2 young patients (aged <40 years) who developed severe dilated cardiomyopathy after chronic amphetamine use. Thorough psychological evaluations demonstrated favorable features with patients being reliable and committed to their health problems. A left ventricular assist device (HeartMate II; Abbott, Chicago, IL) was implanted in the patients shortly after admission to optimize hemodynamic support and evaluate the potential for recovery. Within less than 1 year, significant improvement was achieved and successful explantation of left ventricular assist device was performed in both patients.

      Résumé

      L’exposition aux drogues de synthèse, telles les amphétamines, peut avoir des conséquences graves sur le système cardiovasculaire. Le pronostic des jeunes adultes ayant une cardiomyopathie liée aux amphétamines demeure mauvais. Nous présentons deux cas de patients jeunes (< 40 ans) qui ont développé une cardiomyopathie dilatée grave après une consommation prolongée d’amphétamines. Des évaluations psychologiques approfondies ont démontré des caractéristiques favorables en raison de la fiabilité des patients et de leur engagement à résoudre leurs problèmes de santé. Un dispositif d’assistance ventriculaire gauche (HeartMate II, Abbott, Chicago, IL) a été implanté chez les patients peu après leur admission pour optimiser la suppléance hémodynamique et évaluer le potentiel de rétablissement. En moins d'un an, d’importantes améliorations ont été obtenues et l’explantation des dispositifs d’assistance ventriculaire gauche s’est avérée une réussite chez les deux patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Paratz E.D.
        • Cunningham N.J.
        • Macisaac A.I.
        The cardiac complications of methamphetamines.
        Heart Lung Circ. 2016; 25: 325-332
        • Kueh S.A.
        • Gabriel R.S.
        • Lund M.
        • et al.
        Clinical characteristics and outcomes of patients with amphetamine-associated cardiomyopathy in South Auckland, New Zealand.
        Heart Lung Circ. 2016; 25: 1087-1093
        • Sutter M.E.
        • Gaedigk A.
        • Albertson T.E.
        • et al.
        Polymorphism in CYP2D6 may predict methamphetamine related heart failure.
        Clin Toxicol. 2013; 51: 540-544
        • Schürer S.
        • Klingel K.
        • Sandri M.
        • et al.
        Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy.
        JACC Heart Fail. 2017; 5: 435-445
        • Pujol-López M.
        • Ortega-Paz L.
        • Flores-Umanzor E.J.
        • Perea R.J.
        • Bosch X.
        Cardiac magnetic resonance as an alternative to endomyocardial biopsy to predict recoverability of left ventricular function in methamphetamine-associated cardiomyopathy.
        JACC Heart Fail. 2017; 5: 853-854